Enlivex Therapeutics (ENLV) 20-F29 Apr 222021 FY Annual report (foreign)Financial data

Company Profile

Document And Entity Information

Document And Entity Information	12 Months Ended
Document And Entity Information	Dec. 31, 2021shares
Document Information Line Items
Entity Registrant Name	Enlivex Therapeutics Ltd.
Trading Symbol	ENLV
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	18,331,507
Amendment Flag	false
Entity Central Index Key	0001596812
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-36578
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	14 Einstein Street
Entity Address, City or Town	Nes Ziona
Entity Address, Country	IL
Entity Address, Postal Zip Code	7403618
Title of 12(b) Security	Ordinary Shares, par value of NIS 0.40
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	U.S. GAAP
Auditor Firm ID	1024
Auditor Name	Yarel + Partners
Auditor Location	Tel-Aviv, Israel
Business Contact
Document Information Line Items
Entity Address, Address Line One	14 Einstein Street
Entity Address, City or Town	Nes Ziona
Entity Address, Country	IL
Entity Address, Postal Zip Code	7403618
Contact Personnel Name	Mr. Oren Hershkovitz
City Area Code	+972
Local Phone Number	2.6208072
Contact Personnel Email Address	Oren@enlivexpharm.com
Contact Personnel Fax Number	+972.2.6208070

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents (note 3)	$ 11,202	$ 5,673
Short term deposits (note 4)	10,004	30,034
Marketable securities	62,924
Prepaid expenses and other receivables	2,199	1,243
Cash held with respect to CVR Agreement (notes 3 & 8)	113	1,171
Total Current Assets	86,442	38,121
Non-Current Assets
Property and equipment, net (note 5)	2,530	1,481
Other assets (notes 6 & 9)	6,174	756
Total Non-Current Assets	8,704	2,237
TOTAL ASSETS	95,146	40,358
Current Liabilities
Accounts payable trade (note 14)	878	463
Accrued expenses and other liabilities (note 7)	3,727	2,738
CVR holders (note 8)	113	1,171
Total Current Liabilities	4,718	4,372
Non-Current Liabilities
Other long-term Liabilities (note 9)	5,389	499
Total Non-Current Liabilities	5,389	499
Commitments and Contingent Liabilities (note 10)
TOTAL LIABILITIES	10,107	4,871
SHAREHOLDERS’ EQUITY
Ordinary shares of NIS 0.40 par value: (note 11) Authorized: 45,000,000 shares as of December 31, 2021 and 2020; Issued and outstanding: 18,331,507 and 14,587,934 as of December 31, 2021 and 2020, respectively;	2,107	1,646
Additional paid in capital	133,796	70,361
Foreign currency translation reserve	1,101	977
Accumulated deficit	(51,965)	(37,497)
TOTAL SHAREHOLDERS’ EQUITY	85,039	35,487
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 95,146	$ 40,358

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - ₪ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Ordinary shares, par value (in New Shekels per share)	₪ 0.4	₪ 0.4
Ordinary shares, authorized	45,000,000	45,000,000
Ordinary shares, issued	18,331,507	14,587,934
Ordinary shares, outstanding	18,331,507	14,587,934

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues
Operating expenses:
Research and development expenses, net (note 16a)	12,881	6,086	5,604
General and administrative expenses (note 16b)	6,407	3,699	3,015
Total operating expenses	19,288	9,785	8,619
Operating (loss)	(19,288)	(9,785)	(8,619)
Other income (expenses), net (note 16c)	4,820	(2,039)	(765)
Net (loss)	(14,468)	(11,824)	(9,384)
Other comprehensive gain (loss)
Exchange differences arising from translating financial statements from functional to presentation currency	124	2,277	951
Total other comprehensive gain (loss)	124	2,277	951
Total comprehensive (loss)	$ (14,344)	$ (9,547)	$ (8,433)
Basic & diluted (loss) per share (in Dollars per share)	$ (0.81)	$ (0.9)	$ (1.11)
Weighted average number of shares outstanding (in Shares)	17,859,713	13,169,208	8,649,486

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders’ Equity - USD ($) $ in Thousands	Ordinary Shares	Preferred Shares	Additional paid in capital	Currency translation reserve	Accumulated deficit	Total
Balance at Dec. 31, 2018	$ 396	$ 524	$ 27,326	$ (2,251)	$ (16,289)	$ 9,706
Balance (in Shares) at Dec. 31, 2018	3,509,405	4,958,705
Conversion of Preferred Shares to Ordinary Shares	$ 605	$ (524)	(81)
Conversion of Preferred Shares to Ordinary Shares (in Shares)	5,479,547	(4,958,705)
Issuance of shares upon exercise of warrants	$ 2		247			249
Issuance of shares upon exercise of warrants (in Shares)	20,348
Issuance of shares for cash consideration of $8,362 net of $655 issuance costs	$ 76		7,631			7,707
Issuance of shares for cash consideration of $8,362 net of $655 issuance costs (in Shares)	682,631
Shares issued in conjunction with share option exercise	$ 25		574			599
Shares issued in conjunction with share option exercise (in Shares)	221,641
Issuance of shares in connection with the merger	$ 47		597			644
Issuance of shares in connection with the merger (in Shares)	420,554
Stock based compensation			810			810
Other comprehensive gain				951		951
Net loss					(9,384)	(9,384)
Balance at Dec. 31, 2019	$ 1,151		37,104	(1,300)	(25,673)	11,282
Balance (in Shares) at Dec. 31, 2019	10,334,126
Issuance of shares and warrants for cash consideration of $26,968 net of $2,501 issuance costs	$ 382		24,085			24,467
Issuance of shares and warrants for cash consideration of $26,968 net of $2,501 issuance costs (in Shares)	3,286,416
Exercise of options	$ 4		97			$ 101
Exercise of options (in Shares)	37,746					929,646
Exercise of warrants	$ 109		8,405			$ 8,514
Exercise of warrants (in Shares)	929,646
Stock based compensation			670			670
Stock based compensation (in Shares)
Other comprehensive gain				2,277		2,277
Net loss					(11,824)	(11,824)
Balance at Dec. 31, 2020	$ 1,646		70,361	977	(37,497)	35,487
Balance (in Shares) at Dec. 31, 2020	14,587,934
Issuance of shares and warrants for cash consideration of $57,629 net of $4,455 issuance costs	$ 352		52,822			53,174
Issuance of shares and warrants for cash consideration of $57,629 net of $4,455 issuance costs (in Shares)	2,848,629
Exercise of options	$ 5		101			$ 106
Exercise of options (in Shares)	39,131					855,813
Exercise of warrants	$ 104		7,598			$ 7,702
Exercise of warrants (in Shares)	855,813
Stock based compensation			2,914			2,914
Other comprehensive gain				124		124
Net loss					(14,468)	(14,468)
Balance at Dec. 31, 2021	$ 2,107		$ 133,796	$ 1,101	$ (51,965)	$ 85,039
Balance (in Shares) at Dec. 31, 2021	18,331,507

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Shareholders’ Equity (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Cash consideration	$ 57,629	$ 26,968	$ 8,362
Issuance costs	$ 4,455	$ 2,501	$ 655

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (14,468)	$ (11,824)	$ (9,384)
Adjustments required to reflect net cash used in operating activities:
Depreciation	546	286	206
Income on marketable securities	(5,590)
Non-cash operating lease expense	413	167	168
Decrease in retirement benefit obligations			(7)
Loss on sale of property and equipment			75
Share-based compensation	2,914	670	810
Changes in fair value of warrants			51
Changes in operating asset and liability items:
(Increase) decrease in prepaid expenses and other receivables	(1,249)	1,823	318
Increase in accounts payable trade	442	36	114
(Decrease) increase in accrued expenses and other liabilities	(466)	(2,022)	775
Operating lease liabilities	(84)	(143)	(167)
Net cash used in operating activities	(17,542)	(11,007)	(7,041)
Cash flows from investing activities
Purchase of property and equipment	(1,625)	(1,019)	(193)
Proceeds from sale of property and equipment			4
(Release) investment in short-term bank deposits, net	20,030	(19,958)	(7,714)
Purchases of marketable securities	(104,417)
Proceeds from sale of marketable securities	47,604
Net cash received in the issuance of shares for the net assets of Bioblast Pharma Ltd.			1,544
Net cash used in investing activities	(38,408)	(20,977)	(6,359)
Cash flows from financing activities
Proceeds from issuance of shares and warrants, net	53,174	24,467	7,707
Proceeds from exercise of warrants	7,702	8,514
Proceeds from exercise of options	106	101	599
Net cash provided by financing activities	60,982	33,082	8,306
Increase (decrease) in cash, cash equivalents and restricted cash	5,032	1,098	(5,094)
Cash, cash equivalents and restricted cash - beginning of year	7,012	5,524	9,792
Exchange rate differences on cash, cash equivalents and restricted cash	(408)	390	826
Cash, cash equivalents and restricted cash - end of year	11,636	7,012	5,524
Non-cash investing and financing activities:
Conversion of preferred stock to ordinary shares			525
Conversion of 6% preference on preferred shares to ordinary shares			2,071
Issuance of ordinary shares upon exercise of warrants			249
Issuance of shares to the former shareholders of Bioblast Pharma Ltd.			47
Net assets acquired in the issuance of shares for the net assets of Bioblast Pharma Ltd. excluding cash, cash equivalents and restricted cash:
Assets acquired			(2,632)
Less - liabilities assumed			3,532
Net assets acquired in the issuance of shares for the net assets of Bioblast Pharma Ltd. excluding cash, cash equivalents and restricted cash			900
Cash paid for taxes
Cash received for interest, net	$ 39	$ 160	$ 112

General Information

General Information	12 Months Ended
General Information	Dec. 31, 2021
General Information [Abstract]
GENERAL INFORMATION	NOTE 1 – GENERAL INFORMATION a. General Enlivex Therapeutics Ltd. (the “Parent” and, including its consolidated subsidiaries, “we”, “us”, “our” or the “ Company Merger As a result of the Merger, the financial statements of the Company prior to the Merger are the historical financial statements of Enlivex R&D whereas the financial statements of the Company after the Merger reflect the results of the consolidated operations. Enlivex R&D was incorporated in September 2005 under the laws of the State of Israel. In January 2015, Bioblast Pharma Inc. was established in the State of Delaware as a wholly owned subsidiary of the Parent, and, on July 1, 2020 changed its name to Enlivex Therapeutics Inc. On June 21, 2021 Enlivex Therapeutics RDO Ltd. was established in Israel as a wholly owned subsidiary of the Parent. The Company is a clinical stage macrophage reprogramming immunotherapy company, developing Allocetra TM Allocetra TM The Company’s ordinary shares are traded under the symbol “ENLV” on both the Nasdaq Capital Market and on the Tel Aviv Stock Exchange. b. Financial resources The Company devotes substantially all of its efforts toward research and development activities and raising capital. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. Research and development activities have required significant capital investment since the Company’s inception. The Company expects its operations to continue to require additional cash investment to pursue the Company’s research and development activities, including preclinical studies, formulation development, clinical trials and related drug manufacturing. The Company has not generated any revenues or product sales and has not achieved profitable operations or positive cash flow from operations. The Company’s has incurred net losses since its inception, and, as of December 31, 2021, had an accumulated deficit of $52 million. The Company raised $53.2 million (after deducting placement agent fees and offering expenses) in conjunction with a securities offering during 2021 and an additional $7.8 million from exercises of options and warrants. However, the Company expects to continue to incur losses for at least the next several years, and, over that period, the Company will need to raise additional financing or enter into partnerships to fund its development. If the Company is not able to achieve its funding requirements, it may be required to reduce discretionary spending, may not be able to continue the development of its product candidates or may be required to delay part of its development programs, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The Company’s ability to continue to operate in the long term is dependent upon additional financial support. There can be no assurances that additional financing will be secured or, if secured, will be on favorable terms. The ability of the Company to transition to profitability in the longer term is dependent on developing products and product revenues to support its expenses. The Company’s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company’s products for at least twelve months from the filing of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, of which these audited consolidated financial statements form a part. The Company may determine, however, to raise additional capital during such period as its Board of Directors deems prudent.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The Company’s audited consolidated financial statements as of December 31, 2021 and 2020 and for each of the years in the three-year period ended December 31, 2021 have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. The significant accounting policies described below have been applied on a consistent basis for all years presented. The financial statements have been prepared on the basis of historical cost, subject to adjustment of financial assets and liabilities to their fair value through profit or loss. The Company classifies its expenses on the statement of comprehensive loss based on the operating characteristics of such expenses. Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions, it also requires that management exercise its judgment in applying the Company’s accounting policies. The Company’s management believes that the estimates, judgments and assumptions used were reasonable based upon information available at the time they were made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts in the statements of operations during each reporting period. Actual results could differ materially from those estimates. Functional currency and translation to the reporting currency The functional currency of the Company is the U.S. dollar because the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. The functional currency of Enlivex R&D was the New Israeli Shekel (“NIS”), but the Company reassessed the functional currency and determined that the factors now supported the U.S. dollar as the functional currency prospectively from September 30, 2021. Significant elements in the decision to effect the functional currency change involved (i) a change in the Company’s business strategy resulting from a planned initiation of oncology clinical trials (ii) the newly-developed frozen formulation of Allocetra, which removed the constraints of short shelf life and long-term storage of the liquid formulation and enabled the conduct of clinical trials for Sepsis and Oncology outside of Israel. Additionally, the Company’s sources of financing are the U.S. capital markets and U.S. dollar-denominated government grants from the State of Israel, and all of the Company’s budgeting and planning are conducted solely in U.S. dollars, all of which contributed to the decision to change the Company’s functional currency. Monetary assets and liabilities denominated in foreign currencies were translated into U.S. dollars using exchange rates in effect at the balance sheet date. Balances related to non-monetary assets and liabilities are based on translated amounts as of the date of the change, and non-monetary assets acquired and liabilities incurred after September 30, 2021 were translated at the approximate exchange rate prevailing at the date of the transaction. Transactions included in the statement of income until the date of change were translated at average exchange rates during the applicable period, and transactions after September 30, 2021 were translated at the approximate exchange rate in effect at the time of the transaction. Gains or losses resulting from translation adjustments until September 30, 2021 are reported in other comprehensive income (loss). The following table presents data regarding U.S. dollar exchange rates: 2021 2020 2019 At December 31, 1 U.S. $ = NIS 3.110 NIS 3.215 NIS 3.456 Increase (decrease) during the year (3.3 )% (7.0 )% (7.8 )% Average yearly exchange rates NIS 3.2302 NIS 3.442 NIS 3.564 Cash and cash equivalents Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. Restricted cash: Amounts included in restricted cash are held in interest bearing saving accounts and represent cash amounts required to be set aside by a contractual agreement for the rental of the Company’s premises and for credit cards and cash amounts required to be set aside by other contractual agreements. Marketable Securities. The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in mutual funds that are classified based on the nature of their underlying securities and their availability for use in current operations. The Company’s marketable equity securities are measured at fair value with gains and losses recognized in other income/(expense), net. Net gain recognized on equity securities for the years ended December 31, 2021, 2020 and 2019 were $5,590 thousands, $0 and $0 of which $4,599 thousand, $0 and $0, respectively, were not realized. Property and equipment Property and equipment are stated at historical cost less depreciation. Assets are depreciated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows: % Computers 33 Office furniture and equipment 7 Leasehold improvements 16.67 Laboratory equipment 15-30 Impairment of non-financial assets The long-lived assets of the Company are reviewed for impairment in accordance with ASC 360, “Property, Plant, and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2021, 2020, and 2019, no impairment losses were identified. Leases In accordance with ASU No. 2016-02, Leases (Topic 842), right-of-use (“ROU”) assets represent our right to use the underlying leased assets over the lease term, and lease liabilities represent our obligation to make lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. Operating lease ROU assets are reported in other assets, and operating lease liabilities are reported in accounts payable and accrued liabilities (current), and other long-term liabilities (non-current) in our consolidated balance sheets. Because the Company’s leases do not provide an implicit interest rate, the Company, with input from a third-party appraiser, uses its estimated incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Short-term leases (with a term of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. The Company’s lease agreements include rental payments that adjust periodically for inflation and do not contain any material residual value guarantees or material restrictive covenants. Stock-based compensation The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. Employee benefits The Company is required by Israeli law to make severance payments to Israeli employees upon their dismissal or termination of employment in certain circumstances. The Company operates a number of post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a fund administered by a separate and independent entity so that the Company has no legal or constructive obligation to pay additional contributions if such fund does not contain sufficient assets to pay all employees the benefits to which they may be entitled relating to employee service in the current and prior periods. The fund assets are not included in the Company’s consolidated balance sheets. The Company operates pension and severance compensation plans subject to Section 14 of the Israeli Severance Pay Law. The plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the plans meet the definition of a defined contribution plan. Short term employee benefits - Labor laws in Israel entitle every employee to vacation days, paid sick leave and recreation pay, computed annually. The Company recognizes a liability and an expense in respect of vacation and recreation pay based on the individual entitlement of each employee. Revenue Recognition The Company has not yet generated any revenue from product sales or otherwise. Research and development expenses, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs, consulting fees and facilities and overhead costs. All costs associated with research and developments are expensed as incurred. As of December 31, 2021, the Company had not yet capitalized development expenses. Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use. Grants received from Israel Innovation Authority, Ministry of Industry, Trade and Labor (the “IIA”), are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. Clinical trial expenses are charged to research and development expense as incurred. The Company’s objective is to reflect the appropriate trial expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made, the payments are recorded as assets, which are expensed as services are rendered. Preclinical and Clinical Trial Accruals The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, clinical trial sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. General and administrative General and administrative expenses consist of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead, such as facilities and equipment rent and maintenance, insurance costs allocated to general and administrative expenses, costs of patent applications, maintenance, depreciation expense, marketing costs, and other miscellaneous expenses which are allocated to general and administrative expense. Patents The Company expenses all costs associated with patents (including application fees, and the legal and consulting expenses related to making such applications) for product candidates under development as incurred. As a result of the Company’s research and development efforts, the Company regularly applies for patents to protect proprietary technology and inventions. To date, the Company has not capitalized patent costs. The Company recorded charges to general and administrative expenses in the accompanying statements of operations and comprehensive loss of approximately $373 thousand, $374 thousand and $120 thousand for the years ended December 31, 2021, 2020 and 2019, respectively, related to patent costs. Income taxes The Company accounts for income taxes in accordance with ASC 740-10 “Accounting for Income Taxes”, which requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. As the Company is currently engaged primarily in development activities and is not expected to generate taxable income in the foreseeable future, the Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable value. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2021, the Company recorded a liability of $705 thousand for uncertain tax positions. The Company does not expect that the amount of uncertain tax positions will change within the next year. Loss per share Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential shares in accordance with ASC 260, “Earnings per Share.” All outstanding preferred stock, options and warrants in the years 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all years presented. For the years ended December 31, 2021, 2020 and 2019, the total weighted average number of shares related to outstanding potential shares excluded from the calculations of diluted net loss per share were 2,910,491, 3,526,214 and 3,247,127, respectively. The following data show the amounts used in computing income (loss) per share and the effect on income (loss): (in thousands except share and per share data) Year ended December 31, 2021 2020 2019 Basic and diluted (loss) per share: (Loss) from continuing operations $ (14,468 ) $ (11,824 ) $ (9,384 ) Interest of 6% to Cumulative Preferred Stock - - (198 ) $ (14,468 ) $ (11,824 ) $ (9,582 ) Number of common shares at the beginning of the year 14,587,934 10,334,126 3,509,405 Weighted average number of shares issued for cash 2,485,245 2,603,763 518,295 Weighted average number of shares issued in connection with the merger - - 322,617 Weighted average number of stock options exercised 16,715 21,749 80,073 Weighted average number of warrants exercised 769,819 209,570 15,609 Weighted average number of shares issued in connection with conversion of Preferred Shares - - 4,203,487 Number of shares used in per share computation 17,859,713 13,169,208 8,649,486 Basic and diluted net (loss) per share $ (0.81 ) $ (0.90 ) $ (1.11 ) Concentrations of credit risk: The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and bank deposits. Cash and cash equivalents, restricted cash and deposits are invested in major banks in Israel. Such deposits in Israel are not insured. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company has no foreign exchange contracts or any other hedging arrangements as of December 31, 2021. Fair value of financial instruments The Company applies ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), the guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The Company’s financial instruments consist of cash and cash equivalents, restricted cash, deposits, marketable securities, accounts receivable, accounts payable, accrued liabilities, and lease liability. Fair value estimates of these instruments are made at each reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company believes that the fair value of the lease liability approximates its carrying value. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. The financial instruments presented on the balance sheet at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - inputs other than quoted prices included within level 1 that are observable either directly or indirectly. Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). Comprehensive income (loss) Comprehensive loss is the change in shareholders’ equity from transactions and other events and circumstances other than those resulting from investments by shareholders and distributions to shareholders. The Company accounts for comprehensive income (loss) in accordance with ASC 220, “Comprehensive Income”. This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general-purpose financial statements. The Company’s other comprehensive income (loss) is currently composed of gains or losses resulting from translation adjustments, which result from translating the financial statements into U.S. dollars when its functional currency was different than the U.S. dollar. Reclassification Certain comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant impact on the Company’s equity, net income or cash flows. Recently Issued Accounting Standards In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832)- Disclosures by Business Entities about Government Assistance”. This ASU requires annual disclosures for transactions with a government authority that are accounted for by applying a grant or contribution model. These amendments are effective for annual periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. Recently Adopted Accounting Standards Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which removes specific exceptions to the general principles in Topic 740 and simplifies the accounting for income taxes. The adoption of this standard did not have a significant impact on the Company’s consolidated financial statements. Effective January 1, 2021, the Company adopted ASU No. 2020-10, Codification Improvements, which amends a variety of topics in the Accounting Standards Codification to improve consistency and clarify guidance. The adoption of this standard did not have a significant impact on the Company’s consolidated financial statements.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	12 Months Ended
Cash, Cash Equivalents and Restricted Cash	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
CASH, CASH EQUIVALENTS AND RESTRICTED CASH	NOTE 3 – CASH, CASH EQUIVALENTS AND RESTRICTED CASH The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet, including location of amounts reported in the accompanying consolidated balance sheets, that sum to the total of the same such amounts shown in the statement of cash flows. December 31, (in thousands) 2021 2020 Cash held in banks $ 1,199 $ 1,173 Bank deposits in U.S.$ with original maturities of three months or less 10,003 4,500 Total cash and cash equivalents 11,202 5,673 Cash held with respect to CVR Agreement, see note 8 113 1,171 Restricted cash – current – Prepaid expenses and other receivables - 79 Restricted cash – noncurrent – Other assets 321 89 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 11,636 $ 7,012

Short Term Deposits

Short Term Deposits	12 Months Ended
Short Term Deposits	Dec. 31, 2021
Short Term Deposits [Abstract]
SHORT TERM DEPOSITS	NOTE 4 – SHORT TERM DEPOSITS December 31, (in thousands) 2021 2020 Bank deposits in U.S.$ (annual average interest rates 0.6% and 2.1%) $ 10,004 $ 30,034

Property and Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: December 31, (in thousands) 2021 2020 Cost: Laboratory equipment $ 1,891 $ 1,256 Computers 256 169 Office furniture & equipment 192 102 Leasehold improvements 1,521 712 Total cost 3,860 2,239 Accumulated depreciation: Laboratory equipment 960 588 Computers 138 87 Office furniture & equipment 15 5 Leasehold improvements 217 78 Total accumulated depreciation 1,330 758 Depreciated cost $ 2,530 $ 1,481 For the years ended December 31, 2021, 2020 and 2019, depreciation expenses were $546 thousand, $286 thousand and $206 thousand, respectively.

Other Assets

Other Assets	12 Months Ended
Other Assets	Dec. 31, 2021
Other Assets [Abstract]
OTHER ASSETS	NOTE 6 – OTHER ASSETS December 31, (in thousands ) 2021 2020 Restricted cash $ 321 $ 89 Long Term Bank Deposit 3 - Long-term prepaid expenses 161 8 Right-of-Use assets, net 5,689 659 $ 6,174 $ 756

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
Accrued Expenses and Other Liabilities	Dec. 31, 2021
Accrued Expenses and Other Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 7 – ACCRUED EXPENSES AND OTHER LIABILITIES December 31, (in thousands ) 2021 2020 Vacation, convalescence and employees’ bonus accruals $ 1,068 $ 684 Employees and payroll related 519 352 Short term operating lease liabilities 617 203 Accrued expenses and other 1,523 1,499 $ 3,727 $ 2,738

Reverse Merger with Bioblast Ph

Reverse Merger with Bioblast Pharma Ltd.	12 Months Ended
Reverse Merger with Bioblast Pharma Ltd.	Dec. 31, 2021
Reverse Merger With Bioblast Pharma Disclosure [Abstract]
REVERSE MERGER WITH BIOBLAST PHARMA LTD.	NOTE 8 – REVERSE MERGER WITH BIOBLAST PHARMA LTD. As described in Note 1, the Merger completed between Enlivex R&D and Parent was accounted for as an issuance of shares by Enlivex R&D for the net assets of the Parent, accompanied by a recapitalization. Enlivex R&D was considered the acquirer for accounting and financial reporting purposes and acquired the assets and assumed the liabilities of the Parent, and Enlivex R&D gained control of the combined company after the Merger. The annual consolidated financial statements of the Company reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former shareholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. The annual consolidated financial statements include the accounts of the Company and its subsidiaries since the effective date of the Merger and the accounts of Enlivex R&D since inception. Prior to the Merger, on February 19, 2019, the Parent sold its pre-Merger clinical development programs for “Trehalose” to Seelos Therapeutics, Inc. (“Seelos”), a clinical-stage biopharmaceutical company. Under the terms of the agreement between the Parent and Seelos, Seelos paid $1.5 million upon closing and paid an additional $2 million upon the first anniversary of the closing. Seelos has agreed to pay additional milestone payments of up to $17 million upon completion of the related clinical study for Trehalose and approval of a New Drug Application by the FDA, as well as royalties. At the closing of the Merger, the Parent, Enlivex R&D, the Parent’s pre-Merger CEO, as representative of the pre-Merger Parent’s shareholders, and a rights agent entered into a Contingent Value Rights Agreement (the “CVR Agreement”). Pursuant to the CVR Agreement, the Parent’s shareholders immediately prior to the Merger received one CVR for each of the Parent’s ordinary shares held of record immediately prior to the closing of the Merger. Each CVR represents the right to receive payments based on the Parent’s pre-Merger clinical development programs. CVR holders are entitled to receive 100% of any payments up to $20 million received by the Company and 50% of any subsequent consideration in excess of such amount, in each case, net of all related transaction expenses. The estimated fair value of the total consideration of the Merger was $5,152 thousand based on the shares of the Parent outstanding on the Merger date as adjusted per the merger agreement of 420,554 multiplied by the Company’s share price of $12.25 on the date of the Merger. The excess of the fair value of the consideration paid over the fair value of the net assets acquired as detailed below was $4,508 thousand. The following summarizes the estimated fair value of the assets and liabilities acquired at the date of the Merger: (in thousands ) Cash and cash equivalents $ 44 Prepaid expenses and other receivables 632 Cash held with respect to CVR Agreement 1,500 Receivables for the sale of Trehalose 2,000 Trade payables (10 ) Due to CVR Holders (3,500 ) Other current liabilities (22 ) $ 644

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2021
Leases [Abstract]
LEASES	NOTE 9 – LEASES The Company adopted ASU 2016-02, “Leases,” on January 1, 2019, which resulted in the recognition of operating leases on the balance sheet. The Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company’s leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present value of future payments. Lease expenses are recognized on a straight-line basis over the lease term. The Company’s operating leases upon adoption were for laboratory and corporate office space in Jerusalem and in Nes Ziona, Israel and leases of vehicles. Contracts for amendments to the Jerusalem laboratory and office space lease, and the Nes Ziona laboratory and office space lease were entered into During 2019 and 2020, as well as new vehicles leases. On July 29, 2021, the Company entered into an amendment to its lease agreement in Nes Ziona, which added an additional 455 square meters of office space to the existing leased space (875 square meters of offices, laboratory and parking spaces). The lease for the additional 455 square meters is for a period of 63 months, which commenced on August 1, 2021. The lease expires on October 31, 2026 with an option for an extension of 22 months. As of December 31, 2021, the Company was not reasonably certain that it would exercise the extension option and therefore did not include the option in the determination of the total lease term for accounting purposes. The Company exercised its extension option in the Jerusalem lease and extended the term of the lease by an additional 24 months, which commenced on September 1, 2021. On September 19, 2021, the Company entered into a lease agreement for a manufacturing plant space (manufacture of Allocetra TM During 2021, the company entered into two additional vehicle lease agreements. All vehicle lease agreements are for a period of 36 months. Year ended December 31, (in thousands ) 2021 2020 2019 The components of lease expense were as follows: Operating leases expenses $ 698 $ 243 $ 192 Cash flow information related to operating leases follows: Cash used in operating activities $ 449 $ 223 $ 188 Non-cash activity - Right of use assets obtained in exchange for new operating lease liabilities $ 5,446 $ 398 $ 141 December 31, (in thousands ) 2021 2020 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 6,329 $ 920 Accumulated amortization 640 261 Operating lease Right-of-Use assets, net $ 5,689 $ 659 Lease liabilities – current - Accounts payable and accrued liabilities $ 617 $ 203 Lease liabilities – noncurrent 5,389 499 Total operating lease liabilities $ 6,006 $ 702 Weighted average remaining lease term in years 8.6 3.64 Weighted average annual discount rate 3.6 % 11.9 % (in thousands ) Maturities of operating lease liabilities as of December 31, 2021, were as follows: 2022 $ 823 2023 833 2024 711 2025 776 2026 and onwards 3,830 Total undiscounted lease liability 6,973 Less: Imputed interest (967 ) Present value of lease liabilities $ 6,006

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
Commitments and Contingent Liabilities	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 10 – COMMITMENTS AND CONTINGENT LIABILITIES a) Obligation to pay royalties to the State of Israel The Company is required to pay royalties to the State of Israel (represented by the IIA), computed on the basis of proceeds from the sale or license of products for which State grants supported development. These royalties are generally 3% - 5% of sales until repayment of 100% of the grants (linked to the U.S. dollar) received by the Company plus annual interest at the LIBOR rate. The aggregate contingent obligation payable by the Company as of December 31, 2021 was approximately $7.8 million, which represented the gross amount of grants received by the Company from the IIA, including accrued interest as of December 31, 2021. As of December 31, 2021, the Company had not paid any royalties to the IIA. In January 2021, the Company submitted a new grant application to the IIA for reimbursement by the IIA of certain expenses associated with its clinical development program of prevention of cytokine storms and organ dysfunction associated with sepsis for a period commencing January 1, 2021 and ending December 31, 2021 (the “2021 Sepsis Grant Application”). In May 2021 the IIA approved the 2021 Sepsis Grant Application in the total amount of $1.2 million. In March 2020, the Company submitted a grant application to the IIA for funding of its clinical development program of prevention of organ dysfunction and cytokine storms associated with COVID-19. The Company’s application for grants of $597 thousand was approved by the IIA in April 2020 for a period that commenced on April 1, 2020 and ended on March 31, 2021. The approved IIA funding was approximately 30% of the total expenses for the approved clinical program, which the Company executed in Israel. In January 2020, the Company submitted a grant application to the IIA for funding of its clinical development program of prevention of cytokine storms and organ dysfunction associated with Sepsis. The Company’s application for grants of $1 million was approved by the IIA in April 2020 for a period that commenced on April 1, 2020 and ended on March 31, 2021. The approved IIA funding was approximately 30% of the total expenses for the approved clinical program, which the Company executed in Israel. b) On September 7, 2018 the Company entered into an agreement with its Executive Chairman. Pursuant to the agreement, upon termination of the Chairman’s board service, under certain conditions defined in the agreement, the Executive Chairman will be entitled to receive an amount of up to three times his then annual base retainer plus the value of accrued benefits. As of December 31, 2021, no termination liability was accrued or paid. On November 4, 2021 the Company and the Executive Chairman entered into an amendment to the agreement, granting the Executive Chairman 3.33% of future gross proceeds actually received by the Company during the first five (5) years following consummation of a commercial transaction involving the Company or sale of the Company, in each case as defined in the amendment. In the case of a Commercial Transaction, the fee with respect to such commercial transaction would become payable only once the aggregate consideration actually received by the Company in respect of such commercial transaction is equal to or greater than $20 million. c) Litigation From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes that there were no claims or actions pending against the Company at December 31, 2021 which will have, individually or in the aggregate, a material adverse effect on the Company’s business, liquidity, financial position or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company’s business.

Equity

Equity	12 Months Ended
Equity	Dec. 31, 2021
Equity [Abstract]
EQUITY	NOTE 11 – EQUITY a) Ordinary shares confer upon their holders the right to participate and vote in general shareholders’ meetings, to share in the distribution of dividends if declared by the Company and the right to receive assets of the Company upon its liquidation. b) On February 9, 2021, the Company entered into an amended and restated underwriting agreement (the “ Underwriting Agreement Offering The Offering closed on February 12, 2021, on which date the Company completed the issuance of 2,296,107 ordinary shares to Wainwright at a price, including the underwriting discount but before other associated fees, of $18.60 per ordinary share, as set forth in the Underwriting Agreement. On February 17, 2021, Wainwright exercised in part its option to purchase additional ordinary shares and purchased 268,205 ordinary shares at a price, including the underwriting discount but before other associated fees, of $18.60 per share, as set forth in the Underwriting Agreement. In accordance with the Underwriting Agreement, the Company paid Wainwright underwriting discounts and commissions equal to 7% of the gross proceeds received by the Company from the sale of the ordinary shares in the Offering, as well as a management fee equal to 1% of the gross proceeds received by the Company from the sale of the ordinary shares in the Offering. In addition, the Company issued to Wainwright 179,501 warrants to purchase ordinary shares of the Company. The Company has also paid Wainwright approximately $126,000 for various expenses. The net proceeds from the Offering were $47,023 thousand after deducting Wainwright’s fees and other expenses relating to the Offering. c) On October 22, 2020, the Company entered into an at the market offering agreement (the “Sales Agreement”), pursuant to which the Company may, from time to time and at the Company’s option, issue and sell ordinary shares having an aggregate offering price of up to $25 million through a sales agent, subject to certain terms and conditions. All shares sold pursuant to the Sales Agreement were sold pursuant to the Company’s effective shelf registration statement on Form F-3. Under the Sales Agreement, the Company had to pay the sales agent a cash commission of 3% of the gross proceeds of the sale of any shares sold through the sales agent. Between February 5, 2021 and February 9, 2021, the Company received gross proceeds of $6,339,000 from the sale of 284,317 ordinary shares at an average gross price per share of $22.29 under the Sales Agreement. Issuance expenses totaled $192 thousand. On February 9, 2021, the Company terminated the prospectus supplement related to the offer and sale of ordinary shares under the Sales Agreement, but the Sales Agreement remains in full force and effect. To that date, the Company had sold an aggregate of 476,983 ordinary shares under the Sales Agreement, having a gross aggregate offering price of $8,557,000 at a gross average price per share of $17.94. Until such time as the Company files with the SEC a new registration statement on Form F-3 and such registration statement becomes effective, the Company may not offer and sell any additional ordinary shares under the Sales Agreement. d) On March 5, 2020, the Company completed a registered offering pursuant to which certain investors purchased 2,093,750 ordinary shares and 2,093,750 warrants to purchase ordinary shares at a combined offering price of $8 per ordinary share and associated warrant. Net proceeds of the offering were $15,238 thousand after deducting offering expenses. In conjunction with the offerings, the Company also issued to the placement agent warrants to purchase up to 146,563 ordinary shares of the Company. e) On February 26, 2020, the Company completed a registered offering of ordinary shares pursuant to which certain investors purchased 1,000,000 ordinary shares at a price of $8 per share. Net proceeds of the offering were approximately $7,218 thousand after deducting offering expenses. In conjunction with the offering, the Company issued to the placement agent warrants to purchase up to 70,000 ordinary shares. f) Each of the Company’s warrants entitles the holder to exercise such warrant for one ordinary share and does not confer upon such holder any rights as an ordinary shareholder until such holder exercises such holder’s warrants and acquires the ordinary shares. All Company warrants are classified as a component of shareholders’ equity because such warrants are free standing financial instruments that are legally detachable, separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise, requires physical settlement and do not provide any guarantee of value or return. The following table contains additional information concerning warrants activity for the years 2021 and 2020: For the year ended December 31, 2021 2020 Number of warrants Weighted average exercise price Number of warrants Weighted average exercise price Outstanding at beginning of the year 1,407,683 $ 12.33 27,016 $ 180.00 Issued 179,501 $ 25.00 2,310,313 $ 9.09 Forfeited and expired (27,016 ) $ 180.00 - Exercised (855,813 ) $ 9.00 (929,646 ) $ 9.16 Outstanding and exercisable at year-end 704,355 $ 13.18 1,407,683 $ 12.33 Set forth below is data regarding the range of exercise prices and remaining contractual life (in years) for warrants outstanding at December 31, 2021: Exercise Price Number of Outstanding Remaining Life (in years) $ 10 22,750 3.15 $ 9 455,937 0.25 $ 10 46,167 0.25 $ 25 179,501 4.11 704,355

Share-Based Compensation

Share-Based Compensation	12 Months Ended
Share-Based Compensation	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 12 – SHARE-BASED COMPENSATION a) Equity Incentive Plan – general In June 2019, the Company adopted the 2019 Equity Incentive Plan, under which all Ordinary Shares that remained available for future grant under all then existing plans were reserved for issuance with respect to awards that may be granted under the 2019 Equity Incentive Plan. On May 28, 2021, the Company’s Board approved an increase in the number of ordinary shares authorized for issuance to employees, directors and consultants from 2,350,704 to 4,150,704 of which 1,451,043 shares were available for future grant, as of December 31, 2021. Options granted under the 2019 Equity Incentive Plan generally expire after ten years from the date of grant. Upon termination of the holder’s employment or other relationship with the Company, restricted shares/options cease vesting, unvested shares/options forfeit. Underlying shares that are canceled or not exercised or forfeited become available for future grant. b) Stock option information The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the periods indicated: Year ended December 31, 2021 2020 2019 Weighted Average Risk-free interest rate 0.82 % 0.46 % 1.67 % Dividend yield - - - Weighted Average Volatility factor 91.57 % 76.32 % 73.71 % Weighted Average Expected life of the options 5 6 5 The following table contains additional information concerning options granted under the existing stock-option plan: For the year ended December 31, 2021 2020 2019 Number of options Weighted average exercise Number of options Weighted average exercise Number of options Weighted average exercise Outstanding at beginning of the year 1,884,420 $ 5.52 1,625,042 $ 5.72 1,801,418 $ 4.33 Granted 345,500 $ 12.14 360,500 $ 4.46 158,021 $ 8.72 Forfeited and expired (48,242 ) $ 33.11 (63,376 ) $ 6.26 (128,256 ) $ 5.24 Exercised (39,131 ) $ 2.89 (37,746 ) $ 2.69 (221,641 ) $ 2.70 Pre-merger Bioblast options - $ - - $ 15,500 $ 90.17 Outstanding at end of the year 2,142,547 $ 6.02 1,884,420 $ 5.52 1,625,042 $ 5.72 Exercisable at end of the year 1,613,465 $ 4.90 1,283,193 $ 5.15 1,098,691 $ 3.71 Following is a summary of changes in nonvested shares granted: For the year ended December 31, 2020 2020 2019 Number of options Weighted average exercise Number of options Weighted average exercise Number of options Weighted average exercise Balance at beginning of the year 601,227 $ 5.93 526,351 $ 7.03 774,836 $ 5.70 Granted 345,500 $ 12.14 360,500 $ 3.86 158,021 $ 8.72 Vested during the year (385,798 ) $ 7.39 (249,965 ) $ 6.07 (278,250 ) $ 5.21 Forfeited during the year (31,847 ) $ 6.75 (35,659 ) $ 6.24 (128,256 ) $ 5.24 Balance at end of the year 529,082 $ 8.69 601,227 $ 5.93 526,351 $ 7.03 The weighted-average fair values at grant date of options granted during the years ended December 31, 2021, 2020 and 2019 were $6.23, $2.93 and $5.29 respectively. The total unrecognized estimated compensation cost related to non-vested stock options granted until December 31, 2021 was $1,905, which is expected to be recognized over a weighted average period of 1.58 years. c) Set forth below is data regarding the range of exercise prices and remaining contractual life (in years) for options outstanding at December 31, 2021: Exercise price Number of outstanding Remaining Life (in years) Intrinsic Value of No. of options (in thousands ) $ 2.69 649,883 3.42 $ 2,313,584 649,883 $ 3.66 250,000 8.34 646,750 138,890 $ 4.68 55,500 8.25 87,135 13,875 $ 6.22 634,177 5.50 19,025 613,617 $ 8.19 150,000 7.88 - 75,000 $ 8.23 20,000 9.89 - - $ 8.30 15,000 9.60 - - $ 9.02 40,500 8.88 - 10,125 $ 10.12 12,126 6.93 - 9,700 $ 12.21 2,421 7.24 - 1,211 $ 12.23 250,000 9.41 - 69,444 $ 14.00 60,500 9.32 - 30,250 $ 21.40 1,940 7.57 - 970 $ 90.16 500 1.46 - 500 2,142,547 $ 3,066,494 1,613,465 The total intrinsic value of options exercised during 2021 was $336 thousand. d) The following table contains information concerning restricted stock units granted under the existing equity incentive plans: For the year ended December 31, 2021 2020 Number of Weighted average grant date Number of Weighted average grant date Nonvested at beginning of period - $ - - $ - Granted 236,706 $ 10.22 - $ - Vested - $ - - $ - Forfeited (7,375 ) $ 14.67 - $ - Nonvested at end of period 229,331 $ 10.08 - $ - The Company estimates the fair value of restricted stock units based on the closing sales price of the Company’s ordinary shares on the date of grant (or the closing bid price, if no sales were reported). During the years ended December 31, 2021 and 2020, the Company recognized $1,024 thousand and $0, respectively, of share-based compensation expense related to restricted stock units. Total share-based compensation expense related to restricted stock units not yet recognized as of December 31, 2021 was $1,347 thousand, which is expected to be recognized over a weighted average period of 1.63 years. e) The following table summarizes share-based compensation expenses related to grants under the Equity Incentive Plan included in the statements of operations: Year ended December 31, (in thousands ) 2021 2020 2019 Research & development $ 1,210 $ 401 $ 607 General & administrative 1,704 269 203 Total $ 2,914 $ 670 $ 810

Taxes on Income

Taxes on Income	12 Months Ended
Taxes on Income	Dec. 31, 2021
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 13 – TAXES ON INCOME a. The Israeli corporate tax rate is 23%. b. The Company has not been assessed for tax purposes since its incorporation. Tax assessments through the year ended December 31, 2015 are deemed to be final. c. The Parent and its subsidiaries are taxed separately. The Company measures its results for tax purposes in nominal terms in NIS based on financial reporting under Israeli accounting principles, therefore, there are differences between the Company’s taxable income (loss) and income (loss) reflected in these financial statements. The Parent has loss carry-forwards amounting to approximately $47 million deductible only against sale of assets and/or activities in connection with income generated from its pre-Merger clinical development programs for “Trehalose” (see note 8). As of December 31, 2021, the Parent had additional losses carry-forward amounting to approximately $12.2 million, deductible from future taxable income. As of December 31, 2021, Enlivex R&D had losses carry-forward amounting to approximately $41 million, deductible from future taxable income. These losses carry-forward have no expiration date. d. The components of the provision for income taxes are as follows: Year ended December 31, (in thousands ) 2021 2020 2019 Current tax $ - $ - $ - Deferred tax - - - Provision for income taxes, net $ - $ - $ - e. Reconciliation of the theoretical tax expenses: Year ended December 31, (in thousands ) 2021 2020 2019 Loss before taxes $ 14,468 $ 11,824 $ 9,384 Statutory tax rate 23 % 23 % 23 % Tax benefit 3,328 2,720 2,158 Permanent differences 975 635 9,136 Valuation allowance (4,303 ) (3,355 ) (11,294 ) Tax expenses $ - $ - $ - f. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. As of December 31, 2021, the Company had provided a full valuation allowance in respect of deferred tax assets. Management currently believes that because the Company has a history of losses, it is more likely than not that the deferred tax regarding the loss carry-forward and other temporary differences will not be realized for the foreseeable future. Components of the Company’s deferred tax liabilities and assets are as follows: Year ended December 31, (in thousands ) 2021 2020 Tax assets in respect of: $ $ Accrued employees’ and directors’ compensation 308 61 Stock based compensation 746 - Research and development expenses 2,527 1,275 Net loss carryforward 22,444 18,760 Total deferred tax assets 26,025 20,096 Less - valuation allowance (26,025 ) (20,096 ) Deferred tax assets $ - $ -

Balances and Transactions with

Balances and Transactions with Related Parties	12 Months Ended
Balances and Transactions with Related Parties	Dec. 31, 2021
Related Party Transactions [Abstract]
BALANCES AND TRANSACTIONS WITH RELATED PARTIES	NOTE 14 – BALANCES AND TRANSACTIONS WITH RELATED PARTIES Related party’s balances and transactions excluding compensation of members of management and board of directors, were as follows: a) Reported in the accompanying consolidated balance sheets - December 31, (in thousands ) 2021 2020 Current Liabilities - Accounts payable trade $ 275 $ 175 Current Liabilities - Accrued expenses $ 115 $ - b) Related parties’ transactions On May 12, 2019, the Company entered into a research agreement with its Chief Scientific & Medical Officer under which the executive officer undertook to perform a patients’ study according to the terms defined in the agreement. The agreement will terminate upon the completion of the study according to the study protocol and the submission of all reports and other documentation, or if earlier, upon termination by any of the parties pursuant to the terms of the agreement. In the event of early termination for any reason, the Company shall pay the executive officer the following payments: (i) the agreed remuneration for work performed in accordance with the agreement until the date of termination; and (ii) in the event that the termination is not due to a breach of the agreement by the executive officer, the Company shall reimburse the executive officer for all documented expenses arising from non-cancellable commitments incurred prior to such termination. In consideration for the executive officer’s fulfilment of his obligations, the Company has agreed to pay a fixed price for each of the activities performed as defined in the agreement. Total Research and development expenses related to this agreement and included in the Company’s consolidated statement of operations for the years ended December 31 2021, 2020 and 2019 were $1,331 thousand, $522 thousand and $251 thousand.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
Fair Value Measurement	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 15 – FAIR VALUE MEASUREMENT The Company’s financial assets measured at fair value on a recurring basis, consisted of the following types of instruments as of December 31, 2021 and 2020: December 31, 2021 (in thousands ) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 11,202 $ 11,202 $ - $ - Short term deposits 10,004 10,004 - - Cash held with respect to CVR Agreement 113 113 - - Marketable securities 62,924 62,924 - - Restricted cash 321 321 - - Total financial assets $ 84,564 $ 84,564 $ - $ - December 31, 2020 (in thousands ) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,673 $ 5,673 $ - $ - Short term deposits 30,034 30,034 - - Cash held with respect to CVR Agreement 1,171 1,171 - - Restricted cash 168 168 - - Total financial assets $ 37,046 $ 37,046 $ - $ -

Supplementary Financial Stateme

Supplementary Financial Statement Information	12 Months Ended
Supplementary Financial Statement Information	Dec. 31, 2021
Yearly Financial Information Disclosure [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 16 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION a. Research and development expenses – net Year ended December 31, (in thousands ) 2021 2020 2019 Payroll and related expenses $ 5,054 $ 3,183 $ 2,259 Research and development services 4,557 2,438 2,682 Materials 1,505 612 454 Share Based Compensation 1,210 401 607 Depreciation 546 273 198 Other 1,029 394 486 13,901 7,301 6,686 Israel Innovation Authority participation in research and development costs and royalties payable (1,020 ) (1,215 ) (1,082 ) $ 12,881 $ 6,086 $ 5,604 b. General and administrative expenses Year ended December 31, (in thousands ) 2021 2020 2019 Payroll expenses $ 1,138 $ 737 $ 569 Compensation to directors 1,168 862 526 Professional fees 1,080 995 845 Office maintenance and office expenses 167 97 145 Insurance 783 486 243 Share Based Compensation 1,704 269 203 Other 367 253 484 $ 6,407 $ 3,699 $ 3,015 c. Other income (expenses), net Year ended December 31, (in thousands ) 2021 2020 2019 Interest income $ 120 $ 225 $ 238 Income related to marketable securities 5,590 - - Exchange differences, net (562 ) (2,258 ) (945 ) Bank commissions and other expenses (328 ) (6 ) (58 ) $ 4,820 $ (2,039 ) $ (765 )

Events Subsequent to the Balanc

Events Subsequent to the Balance Sheet Date	12 Months Ended
Events Subsequent to the Balance Sheet Date	Dec. 31, 2021
Subsequent Events [Abstract]
EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 17 – EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE The Company evaluated all events and transactions that occurred subsequent to the balance sheet date and prior to the date on which these financial statements were issued, and determined that the following event necessitated disclosure : 1. In January 2022, the Company submitted a new grant application to the IIA to approve expenditure of $4.8 million of its clinical development program for the prevention of cytokine storms and organ dysfunction associated with Sepsis. If approved, the Company expects to receive an IIA grant of up to $1 million for expenses associated with the ongoing sepsis clinical Phase II trial.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The Company’s audited consolidated financial statements as of December 31, 2021 and 2020 and for each of the years in the three-year period ended December 31, 2021 have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. The significant accounting policies described below have been applied on a consistent basis for all years presented. The financial statements have been prepared on the basis of historical cost, subject to adjustment of financial assets and liabilities to their fair value through profit or loss. The Company classifies its expenses on the statement of comprehensive loss based on the operating characteristics of such expenses.
Use of estimates	Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions, it also requires that management exercise its judgment in applying the Company’s accounting policies. The Company’s management believes that the estimates, judgments and assumptions used were reasonable based upon information available at the time they were made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts in the statements of operations during each reporting period. Actual results could differ materially from those estimates.
Functional currency and translation to the reporting currency	Functional currency and translation to the reporting currency The functional currency of the Company is the U.S. dollar because the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. The functional currency of Enlivex R&D was the New Israeli Shekel (“NIS”), but the Company reassessed the functional currency and determined that the factors now supported the U.S. dollar as the functional currency prospectively from September 30, 2021. Significant elements in the decision to effect the functional currency change involved (i) a change in the Company’s business strategy resulting from a planned initiation of oncology clinical trials (ii) the newly-developed frozen formulation of Allocetra, which removed the constraints of short shelf life and long-term storage of the liquid formulation and enabled the conduct of clinical trials for Sepsis and Oncology outside of Israel. Additionally, the Company’s sources of financing are the U.S. capital markets and U.S. dollar-denominated government grants from the State of Israel, and all of the Company’s budgeting and planning are conducted solely in U.S. dollars, all of which contributed to the decision to change the Company’s functional currency. Monetary assets and liabilities denominated in foreign currencies were translated into U.S. dollars using exchange rates in effect at the balance sheet date. Balances related to non-monetary assets and liabilities are based on translated amounts as of the date of the change, and non-monetary assets acquired and liabilities incurred after September 30, 2021 were translated at the approximate exchange rate prevailing at the date of the transaction. Transactions included in the statement of income until the date of change were translated at average exchange rates during the applicable period, and transactions after September 30, 2021 were translated at the approximate exchange rate in effect at the time of the transaction. Gains or losses resulting from translation adjustments until September 30, 2021 are reported in other comprehensive income (loss). The following table presents data regarding U.S. dollar exchange rates: 2021 2020 2019 At December 31, 1 U.S. $ = NIS 3.110 NIS 3.215 NIS 3.456 Increase (decrease) during the year (3.3 )% (7.0 )% (7.8 )% Average yearly exchange rates NIS 3.2302 NIS 3.442 NIS 3.564
Cash and cash equivalents	Cash and cash equivalents Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.
Restricted cash	Restricted cash: Amounts included in restricted cash are held in interest bearing saving accounts and represent cash amounts required to be set aside by a contractual agreement for the rental of the Company’s premises and for credit cards and cash amounts required to be set aside by other contractual agreements.
Marketable Securities	Marketable Securities. The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in mutual funds that are classified based on the nature of their underlying securities and their availability for use in current operations. The Company’s marketable equity securities are measured at fair value with gains and losses recognized in other income/(expense), net. Net gain recognized on equity securities for the years ended December 31, 2021, 2020 and 2019 were $5,590 thousands, $0 and $0 of which $4,599 thousand, $0 and $0, respectively, were not realized.
Property and equipment	Property and equipment Property and equipment are stated at historical cost less depreciation. Assets are depreciated using the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows: % Computers 33 Office furniture and equipment 7 Leasehold improvements 16.67 Laboratory equipment 15-30
Impairment of non-financial assets	Impairment of non-financial assets The long-lived assets of the Company are reviewed for impairment in accordance with ASC 360, “Property, Plant, and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2021, 2020, and 2019, no impairment losses were identified.
Leases	Leases In accordance with ASU No. 2016-02, Leases (Topic 842), right-of-use (“ROU”) assets represent our right to use the underlying leased assets over the lease term, and lease liabilities represent our obligation to make lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. Operating lease ROU assets are reported in other assets, and operating lease liabilities are reported in accounts payable and accrued liabilities (current), and other long-term liabilities (non-current) in our consolidated balance sheets. Because the Company’s leases do not provide an implicit interest rate, the Company, with input from a third-party appraiser, uses its estimated incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Short-term leases (with a term of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. The Company’s lease agreements include rental payments that adjust periodically for inflation and do not contain any material residual value guarantees or material restrictive covenants.
Stock-based compensation	Stock-based compensation The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Employee benefits	Employee benefits The Company is required by Israeli law to make severance payments to Israeli employees upon their dismissal or termination of employment in certain circumstances. The Company operates a number of post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a fund administered by a separate and independent entity so that the Company has no legal or constructive obligation to pay additional contributions if such fund does not contain sufficient assets to pay all employees the benefits to which they may be entitled relating to employee service in the current and prior periods. The fund assets are not included in the Company’s consolidated balance sheets. The Company operates pension and severance compensation plans subject to Section 14 of the Israeli Severance Pay Law. The plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the plans meet the definition of a defined contribution plan. Short term employee benefits - Labor laws in Israel entitle every employee to vacation days, paid sick leave and recreation pay, computed annually. The Company recognizes a liability and an expense in respect of vacation and recreation pay based on the individual entitlement of each employee.
Revenue Recognition	Revenue Recognition The Company has not yet generated any revenue from product sales or otherwise.
Research and development expenses, net	Research and development expenses, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs, consulting fees and facilities and overhead costs. All costs associated with research and developments are expensed as incurred. As of December 31, 2021, the Company had not yet capitalized development expenses. Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use. Grants received from Israel Innovation Authority, Ministry of Industry, Trade and Labor (the “IIA”), are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. Clinical trial expenses are charged to research and development expense as incurred. The Company’s objective is to reflect the appropriate trial expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made, the payments are recorded as assets, which are expensed as services are rendered.
Preclinical and Clinical Trial Accruals	Preclinical and Clinical Trial Accruals The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, clinical trial sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred.
General and administrative	General and administrative General and administrative expenses consist of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead, such as facilities and equipment rent and maintenance, insurance costs allocated to general and administrative expenses, costs of patent applications, maintenance, depreciation expense, marketing costs, and other miscellaneous expenses which are allocated to general and administrative expense.
Patents	Patents The Company expenses all costs associated with patents (including application fees, and the legal and consulting expenses related to making such applications) for product candidates under development as incurred. As a result of the Company’s research and development efforts, the Company regularly applies for patents to protect proprietary technology and inventions. To date, the Company has not capitalized patent costs. The Company recorded charges to general and administrative expenses in the accompanying statements of operations and comprehensive loss of approximately $373 thousand, $374 thousand and $120 thousand for the years ended December 31, 2021, 2020 and 2019, respectively, related to patent costs.
Income taxes	Income taxes The Company accounts for income taxes in accordance with ASC 740-10 “Accounting for Income Taxes”, which requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. As the Company is currently engaged primarily in development activities and is not expected to generate taxable income in the foreseeable future, the Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable value. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2021, the Company recorded a liability of $705 thousand for uncertain tax positions. The Company does not expect that the amount of uncertain tax positions will change within the next year.
Loss per share	Loss per share Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential shares in accordance with ASC 260, “Earnings per Share.” All outstanding preferred stock, options and warrants in the years 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all years presented. For the years ended December 31, 2021, 2020 and 2019, the total weighted average number of shares related to outstanding potential shares excluded from the calculations of diluted net loss per share were 2,910,491, 3,526,214 and 3,247,127, respectively. The following data show the amounts used in computing income (loss) per share and the effect on income (loss): (in thousands except share and per share data) Year ended December 31, 2021 2020 2019 Basic and diluted (loss) per share: (Loss) from continuing operations $ (14,468 ) $ (11,824 ) $ (9,384 ) Interest of 6% to Cumulative Preferred Stock - - (198 ) $ (14,468 ) $ (11,824 ) $ (9,582 ) Number of common shares at the beginning of the year 14,587,934 10,334,126 3,509,405 Weighted average number of shares issued for cash 2,485,245 2,603,763 518,295 Weighted average number of shares issued in connection with the merger - - 322,617 Weighted average number of stock options exercised 16,715 21,749 80,073 Weighted average number of warrants exercised 769,819 209,570 15,609 Weighted average number of shares issued in connection with conversion of Preferred Shares - - 4,203,487 Number of shares used in per share computation 17,859,713 13,169,208 8,649,486 Basic and diluted net (loss) per share $ (0.81 ) $ (0.90 ) $ (1.11 )
Concentrations of credit risk	Concentrations of credit risk: The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and bank deposits. Cash and cash equivalents, restricted cash and deposits are invested in major banks in Israel. Such deposits in Israel are not insured. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company has no foreign exchange contracts or any other hedging arrangements as of December 31, 2021.
Fair value of financial instruments	Fair value of financial instruments The Company applies ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), the guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The Company’s financial instruments consist of cash and cash equivalents, restricted cash, deposits, marketable securities, accounts receivable, accounts payable, accrued liabilities, and lease liability. Fair value estimates of these instruments are made at each reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company believes that the fair value of the lease liability approximates its carrying value. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. The financial instruments presented on the balance sheet at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - inputs other than quoted prices included within level 1 that are observable either directly or indirectly. Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
Comprehensive income (loss)	Comprehensive income (loss) Comprehensive loss is the change in shareholders’ equity from transactions and other events and circumstances other than those resulting from investments by shareholders and distributions to shareholders. The Company accounts for comprehensive income (loss) in accordance with ASC 220, “Comprehensive Income”. This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general-purpose financial statements. The Company’s other comprehensive income (loss) is currently composed of gains or losses resulting from translation adjustments, which result from translating the financial statements into U.S. dollars when its functional currency was different than the U.S. dollar.
Reclassification	Reclassification Certain comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant impact on the Company’s equity, net income or cash flows.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832)- Disclosures by Business Entities about Government Assistance”. This ASU requires annual disclosures for transactions with a government authority that are accounted for by applying a grant or contribution model. These amendments are effective for annual periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which removes specific exceptions to the general principles in Topic 740 and simplifies the accounting for income taxes. The adoption of this standard did not have a significant impact on the Company’s consolidated financial statements. Effective January 1, 2021, the Company adopted ASU No. 2020-10, Codification Improvements, which amends a variety of topics in the Accounting Standards Codification to improve consistency and clarify guidance. The adoption of this standard did not have a significant impact on the Company’s consolidated financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
Significant Accounting Policies (Tables)	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of U.S. dollar exchange rate	2021 2020 2019 At December 31, 1 U.S. $ = NIS 3.110 NIS 3.215 NIS 3.456 Increase (decrease) during the year (3.3 )% (7.0 )% (7.8 )% Average yearly exchange rates NIS 3.2302 NIS 3.442 NIS 3.564
Schedule of annual depreciation rates	% Computers 33 Office furniture and equipment 7 Leasehold improvements 16.67 Laboratory equipment 15-30
Schedule of computing income (loss) per share and the effect on income (loss)	(in thousands except share and per share data) Year ended December 31, 2021 2020 2019 Basic and diluted (loss) per share: (Loss) from continuing operations $ (14,468 ) $ (11,824 ) $ (9,384 ) Interest of 6% to Cumulative Preferred Stock - - (198 ) $ (14,468 ) $ (11,824 ) $ (9,582 ) Number of common shares at the beginning of the year 14,587,934 10,334,126 3,509,405 Weighted average number of shares issued for cash 2,485,245 2,603,763 518,295 Weighted average number of shares issued in connection with the merger - - 322,617 Weighted average number of stock options exercised 16,715 21,749 80,073 Weighted average number of warrants exercised 769,819 209,570 15,609 Weighted average number of shares issued in connection with conversion of Preferred Shares - - 4,203,487 Number of shares used in per share computation 17,859,713 13,169,208 8,649,486 Basic and diluted net (loss) per share $ (0.81 ) $ (0.90 ) $ (1.11 )

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	12 Months Ended
Cash, Cash Equivalents and Restricted Cash (Tables)	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Schedule of cash, cash equivalents and restricted cash	December 31, (in thousands) 2021 2020 Cash held in banks $ 1,199 $ 1,173 Bank deposits in U.S.$ with original maturities of three months or less 10,003 4,500 Total cash and cash equivalents 11,202 5,673 Cash held with respect to CVR Agreement, see note 8 113 1,171 Restricted cash – current – Prepaid expenses and other receivables - 79 Restricted cash – noncurrent – Other assets 321 89 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 11,636 $ 7,012

Short Term Deposits (Tables)

Short Term Deposits (Tables)	12 Months Ended
Short Term Deposits (Tables)	Dec. 31, 2021
Short Term Deposits [Abstract]
Schedule of short term deposits	December 31, (in thousands) 2021 2020 Bank deposits in U.S.$ (annual average interest rates 0.6% and 2.1%) $ 10,004 $ 30,034

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, (in thousands) 2021 2020 Cost: Laboratory equipment $ 1,891 $ 1,256 Computers 256 169 Office furniture & equipment 192 102 Leasehold improvements 1,521 712 Total cost 3,860 2,239 Accumulated depreciation: Laboratory equipment 960 588 Computers 138 87 Office furniture & equipment 15 5 Leasehold improvements 217 78 Total accumulated depreciation 1,330 758 Depreciated cost $ 2,530 $ 1,481

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
Other Assets (Tables)	Dec. 31, 2021
Other Assets [Abstract]
Schedule of other assets	December 31, (in thousands ) 2021 2020 Restricted cash $ 321 $ 89 Long Term Bank Deposit 3 - Long-term prepaid expenses 161 8 Right-of-Use assets, net 5,689 659 $ 6,174 $ 756

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Liabilities (Tables)	Dec. 31, 2021
Accrued Expenses and Other Liabilities Table [Abstract]
Schedule of accrued expenses and other liabilities	December 31, (in thousands ) 2021 2020 Vacation, convalescence and employees’ bonus accruals $ 1,068 $ 684 Employees and payroll related 519 352 Short term operating lease liabilities 617 203 Accrued expenses and other 1,523 1,499 $ 3,727 $ 2,738

Reverse Merger with Bioblast _2

Reverse Merger with Bioblast Pharma Ltd. (Tables)	12 Months Ended
Reverse Merger with Bioblast Pharma Ltd. (Tables)	Dec. 31, 2021
Reverse Merger With Bioblast Pharma Disclosure [Abstract]
Schedule of estimated fair value of the assets and liabilities	(in thousands ) Cash and cash equivalents $ 44 Prepaid expenses and other receivables 632 Cash held with respect to CVR Agreement 1,500 Receivables for the sale of Trehalose 2,000 Trade payables (10 ) Due to CVR Holders (3,500 ) Other current liabilities (22 ) $ 644

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2021
Leases [Abstract]
Schedule of operating lease expense	Year ended December 31, (in thousands ) 2021 2020 2019 The components of lease expense were as follows: Operating leases expenses $ 698 $ 243 $ 192 Cash flow information related to operating leases follows: Cash used in operating activities $ 449 $ 223 $ 188 Non-cash activity - Right of use assets obtained in exchange for new operating lease liabilities $ 5,446 $ 398 $ 141
Schedule of operating lease related activities	December 31, (in thousands ) 2021 2020 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 6,329 $ 920 Accumulated amortization 640 261 Operating lease Right-of-Use assets, net $ 5,689 $ 659 Lease liabilities – current - Accounts payable and accrued liabilities $ 617 $ 203 Lease liabilities – noncurrent 5,389 499 Total operating lease liabilities $ 6,006 $ 702 Weighted average remaining lease term in years 8.6 3.64 Weighted average annual discount rate 3.6 % 11.9 % (in thousands ) Maturities of operating lease liabilities as of December 31, 2021, were as follows: 2022 $ 823 2023 833 2024 711 2025 776 2026 and onwards 3,830 Total undiscounted lease liability 6,973 Less: Imputed interest (967 ) Present value of lease liabilities $ 6,006

Equity (Tables)

Equity (Tables)	12 Months Ended
Equity (Tables)	Dec. 31, 2021
Equity [Abstract]
Schedule of exercise prices and remaining contractual life (in years)	For the year ended December 31, 2021 2020 Number of warrants Weighted average exercise price Number of warrants Weighted average exercise price Outstanding at beginning of the year 1,407,683 $ 12.33 27,016 $ 180.00 Issued 179,501 $ 25.00 2,310,313 $ 9.09 Forfeited and expired (27,016 ) $ 180.00 - Exercised (855,813 ) $ 9.00 (929,646 ) $ 9.16 Outstanding and exercisable at year-end 704,355 $ 13.18 1,407,683 $ 12.33
Schedule of exercise prices and remaining contractual life (in years)	Exercise Price Number of Outstanding Remaining Life (in years) $ 10 22,750 3.15 $ 9 455,937 0.25 $ 10 46,167 0.25 $ 25 179,501 4.11 704,355

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
Share-Based Compensation (Tables)	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Schedule of fair value of stock option weighted-average assumptions	Year ended December 31, 2021 2020 2019 Weighted Average Risk-free interest rate 0.82 % 0.46 % 1.67 % Dividend yield - - - Weighted Average Volatility factor 91.57 % 76.32 % 73.71 % Weighted Average Expected life of the options 5 6 5
Schedule of options granted under the existing stock-option plans	For the year ended December 31, 2021 2020 2019 Number of options Weighted average exercise Number of options Weighted average exercise Number of options Weighted average exercise Outstanding at beginning of the year 1,884,420 $ 5.52 1,625,042 $ 5.72 1,801,418 $ 4.33 Granted 345,500 $ 12.14 360,500 $ 4.46 158,021 $ 8.72 Forfeited and expired (48,242 ) $ 33.11 (63,376 ) $ 6.26 (128,256 ) $ 5.24 Exercised (39,131 ) $ 2.89 (37,746 ) $ 2.69 (221,641 ) $ 2.70 Pre-merger Bioblast options - $ - - $ 15,500 $ 90.17 Outstanding at end of the year 2,142,547 $ 6.02 1,884,420 $ 5.52 1,625,042 $ 5.72 Exercisable at end of the year 1,613,465 $ 4.90 1,283,193 $ 5.15 1,098,691 $ 3.71
Schedule of changes in nonvested shares granted	For the year ended December 31, 2020 2020 2019 Number of options Weighted average exercise Number of options Weighted average exercise Number of options Weighted average exercise Balance at beginning of the year 601,227 $ 5.93 526,351 $ 7.03 774,836 $ 5.70 Granted 345,500 $ 12.14 360,500 $ 3.86 158,021 $ 8.72 Vested during the year (385,798 ) $ 7.39 (249,965 ) $ 6.07 (278,250 ) $ 5.21 Forfeited during the year (31,847 ) $ 6.75 (35,659 ) $ 6.24 (128,256 ) $ 5.24 Balance at end of the year 529,082 $ 8.69 601,227 $ 5.93 526,351 $ 7.03
Schedule of exercise prices and remaining contractual life	Exercise price Number of outstanding Remaining Life (in years) Intrinsic Value of No. of options (in thousands ) $ 2.69 649,883 3.42 $ 2,313,584 649,883 $ 3.66 250,000 8.34 646,750 138,890 $ 4.68 55,500 8.25 87,135 13,875 $ 6.22 634,177 5.50 19,025 613,617 $ 8.19 150,000 7.88 - 75,000 $ 8.23 20,000 9.89 - - $ 8.30 15,000 9.60 - - $ 9.02 40,500 8.88 - 10,125 $ 10.12 12,126 6.93 - 9,700 $ 12.21 2,421 7.24 - 1,211 $ 12.23 250,000 9.41 - 69,444 $ 14.00 60,500 9.32 - 30,250 $ 21.40 1,940 7.57 - 970 $ 90.16 500 1.46 - 500 2,142,547 $ 3,066,494 1,613,465
schedule of information concerning restricted stock units granted	For the year ended December 31, 2021 2020 Number of Weighted average grant date Number of Weighted average grant date Nonvested at beginning of period - $ - - $ - Granted 236,706 $ 10.22 - $ - Vested - $ - - $ - Forfeited (7,375 ) $ 14.67 - $ - Nonvested at end of period 229,331 $ 10.08 - $ -
Schedule of share-based compensation expenses related to grants under the equity incentive plan	Year ended December 31, (in thousands ) 2021 2020 2019 Research & development $ 1,210 $ 401 $ 607 General & administrative 1,704 269 203 Total $ 2,914 $ 670 $ 810

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
Taxes on Income (Tables)	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes	Year ended December 31, (in thousands ) 2021 2020 2019 Current tax $ - $ - $ - Deferred tax - - - Provision for income taxes, net $ - $ - $ -
Schedule of reconciliation of the theoretical tax expenses	Year ended December 31, (in thousands ) 2021 2020 2019 Loss before taxes $ 14,468 $ 11,824 $ 9,384 Statutory tax rate 23 % 23 % 23 % Tax benefit 3,328 2,720 2,158 Permanent differences 975 635 9,136 Valuation allowance (4,303 ) (3,355 ) (11,294 ) Tax expenses $ - $ - $ -
Schedule of deferred tax liabilities and assets	Year ended December 31, (in thousands ) 2021 2020 Tax assets in respect of: $ $ Accrued employees’ and directors’ compensation 308 61 Stock based compensation 746 - Research and development expenses 2,527 1,275 Net loss carryforward 22,444 18,760 Total deferred tax assets 26,025 20,096 Less - valuation allowance (26,025 ) (20,096 ) Deferred tax assets $ - $ -

Balances and Transactions wit_2

Balances and Transactions with Related Parties (Tables)	12 Months Ended
Balances and Transactions with Related Parties (Tables)	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of consolidated balance sheets	December 31, (in thousands ) 2021 2020 Current Liabilities - Accounts payable trade $ 275 $ 175 Current Liabilities - Accrued expenses $ 115 $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
Fair Value Measurement (Tables)	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of financial assets measured at fair value on a recurring basis	December 31, 2021 (in thousands ) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 11,202 $ 11,202 $ - $ - Short term deposits 10,004 10,004 - - Cash held with respect to CVR Agreement 113 113 - - Marketable securities 62,924 62,924 - - Restricted cash 321 321 - - Total financial assets $ 84,564 $ 84,564 $ - $ - December 31, 2020 (in thousands ) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,673 $ 5,673 $ - $ - Short term deposits 30,034 30,034 - - Cash held with respect to CVR Agreement 1,171 1,171 - - Restricted cash 168 168 - - Total financial assets $ 37,046 $ 37,046 $ - $ -

Supplementary Financial State_2

Supplementary Financial Statement Information (Tables)	12 Months Ended
Supplementary Financial Statement Information (Tables)	Dec. 31, 2021
Yearly Financial Information Disclosure [Abstract]
Schedule of condensed income statement	Year ended December 31, (in thousands ) 2021 2020 2019 Payroll and related expenses $ 5,054 $ 3,183 $ 2,259 Research and development services 4,557 2,438 2,682 Materials 1,505 612 454 Share Based Compensation 1,210 401 607 Depreciation 546 273 198 Other 1,029 394 486 13,901 7,301 6,686 Israel Innovation Authority participation in research and development costs and royalties payable (1,020 ) (1,215 ) (1,082 ) $ 12,881 $ 6,086 $ 5,604 Year ended December 31, (in thousands ) 2021 2020 2019 Payroll expenses $ 1,138 $ 737 $ 569 Compensation to directors 1,168 862 526 Professional fees 1,080 995 845 Office maintenance and office expenses 167 97 145 Insurance 783 486 243 Share Based Compensation 1,704 269 203 Other 367 253 484 $ 6,407 $ 3,699 $ 3,015 c. Other income (expenses), net Year ended December 31, (in thousands ) 2021 2020 2019 Interest income $ 120 $ 225 $ 238 Income related to marketable securities 5,590 - - Exchange differences, net (562 ) (2,258 ) (945 ) Bank commissions and other expenses (328 ) (6 ) (58 ) $ 4,820 $ (2,039 ) $ (765 )

General Information (Details)

General Information (Details) $ in Millions	Dec. 31, 2021USD ($)
General (Textual)
Accumulated deficit	$ 52
Amount raised in conjunction with securities offerings	53.2
Additional amount raised from exercises of options and warrants	$ 7.8

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Net gain recognized on equity securities	$ 5,590	$ 0	$ 0
Net gain on equity securities not realized	4,599	0	0
Related to its patents' costs	$ 373	$ 374	$ 120
Tax benefit, percentage	50.00%
Deferred Tax Liabilities, Gross	$ 705
Weighted average number of shares related to outstanding potential shares excluded from the calculations of diluted net loss per share (in Shares)	2,910,491	3,526,214	3,247,127

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of U.S. dollar exchange rate	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of U.S. dollar exchange rate [Abstract]
At December 31, 1 U.S. $ =	NIS 3.110	NIS 3.215	NIS 3.456
Increase (decrease) during the year	(3.30%)	(7.00%)	(7.80%)
Average yearly exchange rates	NIS 3.2302	NIS 3.442	NIS 3.564

Significant Accounting Polici_5

Significant Accounting Policies (Details) - Schedule of annual depreciation rates	Dec. 31, 2021
Computers [Member]
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Annual depreciation rates	33.00%
Office furniture and equipment [Member]
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Annual depreciation rates	7.00%
Leasehold improvements [Member]
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Annual depreciation rates	16.67%
Laboratory equipment [Member] \| Minimum [Member]
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Annual depreciation rates	15.00%
Laboratory equipment [Member] \| Maximum [Member]
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Annual depreciation rates	30.00%

Significant Accounting Polici_6

Significant Accounting Policies (Details) - Schedule of computing income (loss) per share and the effect on income (loss) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Basic and diluted (loss) per share:
(Loss) from continuing operations (in Dollars)	$ (14,468)	$ (11,824)	$ (9,384)
Interest of 6% to Cumulative Preferred Stock (in Dollars)			(198)
Total (in Dollars)	$ (14,468)	$ (11,824)	$ (9,582)
Number of common shares at the beginning of the year	14,587,934	10,334,126	3,509,405
Weighted average number of shares issued for cash	2,485,245	2,603,763	518,295
Weighted average number of shares issued in connection with the merger			322,617
Weighted average number of stock options exercised	16,715	21,749	80,073
Weighted average number of warrants exercised	769,819	209,570	15,609
Weighted average number of shares issued in connection with conversion of Preferred Shares			4,203,487
Number of shares used in per share computation	17,859,713	13,169,208	8,649,486
Basic and diluted net (loss) per share (in Dollars per share)	$ (0.81)	$ (0.9)	$ (1.11)

Significant Accounting Polici_7

Significant Accounting Policies (Details) - Schedule of computing income (loss) per share and the effect on income (loss) (Parentheticals)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of computing income (loss) per share and the effect on income (loss) [Abstract]
Interest to cumulative preferred stock	6.00%	6.00%	6.00%

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of cash, cash equivalents and restricted cash - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of cash, cash equivalents and restricted cash [Abstract]
Cash held in banks	$ 1,199	$ 1,173
Bank deposits in U.S.$ with original maturities of three months or less (annual average interest rates 0.1% and 0.32%)	10,003	4,500
Total cash and cash equivalents	11,202	5,673
Cash held with respect to CVR Agreement, see note 8	113	1,171
Restricted cash – current – Prepaid expenses and other receivables		79
Restricted cash – noncurrent – Other assets	321	89
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 11,636	$ 7,012

Cash, Cash Equivalents and Re_4

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of cash, cash equivalents and restricted cash (Parentheticals)	Dec. 31, 2021	Dec. 31, 2020
Schedule of cash, cash equivalents and restricted cash [Abstract]
Annual average interest rates	0.10%	0.32%

Short Term Deposits (Details) -

Short Term Deposits (Details) - Schedule of short term deposits - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of short term deposits [Abstract]
Bank deposits in U.S.$ (annual average interest rates 0.6% and 2.1%)	$ 10,004	$ 30,034

Short Term Deposits (Details)_2

Short Term Deposits (Details) - Schedule of short term deposits (Parentheticals)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of short term deposits [Abstract]
Annual average interest rates	0.60%	2.10%

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 546	$ 286	$ 206

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total cost	$ 3,860	$ 2,239
Total accumulated depreciation	1,330	758
Depreciated cost	2,530	1,481
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,891	1,256
Total accumulated depreciation	960	588
Computers [Member]
Property, Plant and Equipment [Line Items]
Total cost	256	169
Total accumulated depreciation	138	87
Office furniture & equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	192	102
Total accumulated depreciation	15	5
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,521	712
Total accumulated depreciation	$ 217	$ 78

Other Assets (Details) - Schedu

Other Assets (Details) - Schedule of other assets - Other Assets [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other Assets (Details) - Schedule of other assets [Line Items]
Restricted cash	$ 321	$ 89
Long Term Bank Deposit	3
Long-term prepaid expenses	161	8
Right-of-Use assets, net	5,689	659
Total	$ 6,174	$ 756

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses and other liabilities - Accrued Expenses and Other Liabilities [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses and other liabilities [Line Items]
Vacation, convalescence and employees’ bonus accruals	$ 1,068	$ 684
Employees and payroll related	519	352
Short term operating lease liabilities	617	203
Accrued expenses and other	1,523	1,499
Accrued expenses and other liabilities, Total	$ 3,727	$ 2,738

Reverse Merger with Bioblast _3

Reverse Merger with Bioblast Pharma Ltd. (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Feb. 19, 2019	Dec. 31, 2021
Reverse Merger With Bioblast Pharma Disclosure [Abstract]
Consideration paid	$ 1,500
Additional consideration paid	2,000
Additional milestone payments	$ 17,000
Business consideration, description	CVR holders are entitled to receive 100% of any payments up to $20 million received by the Company and 50% of any subsequent consideration in excess of such amount, in each case, net of all related transaction expenses.
Estimated fair value of the total considerations		$ 5,152
Adjusted per the merger agreement (in Shares)		420,554
Share price (in Dollars per share)		$ 12.25
Fair value of the net assets		$ 4,508

Reverse Merger with Bioblast _4

Reverse Merger with Bioblast Pharma Ltd. (Details) - Schedule of estimated fair value of the assets and liabilities $ in Thousands	Dec. 31, 2021USD ($)
Schedule of estimated fair value of the assets and liabilities [Abstract]
Cash and cash equivalents	$ 44
Prepaid expenses and other receivables	632
Cash held with respect to CVR Agreement	1,500
Receivables for the sale of Trehalose	2,000
Trade payables	(10)
Due to CVR Holders	(3,500)
Other current liabilities	(22)
Total	$ 644

Leases (Details)

Leases (Details) - m²	Sep. 19, 2021	Dec. 31, 2021	Sep. 01, 2021	Jul. 29, 2021	Jul. 19, 2021
Leases (Details) [Line Items]
Additional square meters of lease agreement (in Square Meters)				455
Lease terms		22 months		63 months
Lease expires date	Sep. 18, 2026
Vehicle lease agreements		36 months
Two Individual [Member]
Leases (Details) [Line Items]
Lease terms	60 months
Nes Ziona [Member]
Leases (Details) [Line Items]
Additional square meters of lease agreement (in Square Meters)				455
Laboratory and Parking Spaces [Member]
Leases (Details) [Line Items]
Additional square meters of lease agreement (in Square Meters)				875
Jerusalem Lease [Member]
Leases (Details) [Line Items]
Lease terms			24 months
Yavne Israel [Member]
Leases (Details) [Line Items]
Lease terms					60 months

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
The components of lease expense were as follows:
Operating leases expenses	$ 698	$ 243	$ 192
Cash flow information related to operating leases follows:
Cash used in operating activities	449	223	188
Non-cash activity - Right of use assets obtained in exchange for new operating lease liabilities	$ 5,446	$ 398	$ 141

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of operating lease related activities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of operating lease related activities [Abstract]
Other assets - Right-of-Use assets	$ 6,329	$ 920
Accumulated amortization	640	261
Operating lease Right-of-Use assets, net	5,689	659
Lease liabilities – current - Accounts payable and accrued liabilities	617	203
Lease liabilities – noncurrent	5,389	499
Total operating lease liabilities	$ 6,006	$ 702
Weighted average remaining lease term in years	8 years 7 months 6 days	3 years 7 months 20 days
Weighted average annual discount rate	3.60%	11.90%
2022	$ 823
2023	833
2024	711
2025	776
2026 and onwards	3,830
Total undiscounted lease liability	6,973
Less: Imputed interest	(967)
Present value of lease liabilities	$ 6,006

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) - USD ($) $ in Millions	Nov. 04, 2021	Sep. 07, 2018	Mar. 31, 2020	Jan. 31, 2020	Dec. 31, 2021
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of royalties in sales					100.00%
Aggregate contingent obligation (in Dollars)					$ 7.8
Grant total amount (in Dollars)					$ 1.2
New grant application, description			the Company submitted a grant application to the IIA for funding of its clinical development program of prevention of organ dysfunction and cytokine storms associated with COVID-19. The Company’s application for grants of $597 thousand was approved by the IIA in April 2020 for a period that commenced on April 1, 2020 and ended on March 31, 2021. The approved IIA funding was approximately 30% of the total expenses for the approved clinical program, which the Company executed in Israel.	the Company submitted a grant application to the IIA for funding of its clinical development program of prevention of cytokine storms and organ dysfunction associated with Sepsis. The Company’s application for grants of $1 million was approved by the IIA in April 2020 for a period that commenced on April 1, 2020 and ended on March 31, 2021. The approved IIA funding was approximately 30% of the total expenses for the approved clinical program, which the Company executed in Israel
Agreement, description		the agreement, upon termination of the Chairman’s board service, under certain conditions defined in the agreement, the Executive Chairman will be entitled to receive an amount of up to three times his then annual base retainer plus the value of accrued benefits. As of December 31, 2021, no termination liability was accrued or paid.
Gross proceeds	3.33%
Commercial transaction (in Dollars)	$ 20
Minimum [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of royalties in sales					3.00%
Maximum [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of royalties in sales					5.00%

Equity (Details)

Equity (Details) - USD ($)	Feb. 12, 2021	Feb. 10, 2021	Feb. 09, 2021	Feb. 17, 2021	Oct. 22, 2020	Mar. 05, 2020	Feb. 26, 2020	Dec. 31, 2021	Dec. 31, 2020
Equity (Details) [Line Items]
Purchase of ordinary shares	2,296,107	476,983	2,296,107	268,205		2,093,750	1,000,000
Additional ordinary shares			344,416
Public price per share (in Dollars per share)	$ 18.6		$ 20	$ 18.6
Sales agent commission, percentage					3.00%			7.00%
Gross proceeds in percentage								1.00%
Warrants to purchase			284,317					179,501
Cost expenses (in Dollars)								$ 126,000
Net offering cost (in Dollars)								$ 47,023,000
Purchase of ordinary shares amount (in Dollars)		$ 8,557,000			$ 25,000,000
Gross proceeds amount (in Dollars)			$ 6,339,000
Gross price per share (in Dollars per share)			$ 22.29
Issuance expense (in Dollars)			$ 192,000
Issuance expenses (in Dollars)		$ 17.94
Warrants to purchase shares								1,407,683	27,016
Ordinary price per share (in Dollars per share)						$ 8
Net proceeds offering (in Dollars)						$ 15,238,000	$ 7,218,000
Price per share (in Dollars per share)							$ 8
Warrant [Member]
Equity (Details) [Line Items]
Warrants to purchase shares						2,093,750	70,000
Placement Agent [Member]
Equity (Details) [Line Items]
Warrants to purchase shares									146,563

Equity (Details) - Schedule of

Equity (Details) - Schedule of warrants activity - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of warrants activity [Abstract]
Number of Warrants, Outstanding beginning of the year	1,407,683	27,016
Weighted average exercise price, Outstanding beginning of the year	$ 12.33	$ 180
Number of Warrants, Issued	179,501	2,310,313
Weighted average exercise price, Issued	$ 25	$ 9.09
Number of Warrants, Forfeited and expired	(27,016)
Weighted average exercise price, Forfeited and expired	$ 180
Number of Warrants, Exercised	(855,813)	(929,646)
Weighted average exercise price, Exercised	$ 9	$ 9.16
Number of Warrants, Outstanding end of the year	704,355	1,407,683
Weighted average exercise price, Outstanding end of the year	$ 13.18	$ 12.33

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of exercise prices and remaining contractual life (in years)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Number of warrants Outstanding	704,355
Exercise Price One [Member] \| Equity Option [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) \| $ / shares	$ 10
Number of warrants Outstanding	22,750
Remaining Contractual Life (in years)	3 years 1 month 24 days
Exercise Price Two [Member] \| Equity Option [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) \| $ / shares	$ 9
Number of warrants Outstanding	455,937
Remaining Contractual Life (in years)	3 months
Exercise Price Three [Member] \| Equity Option [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) \| $ / shares	$ 10
Number of warrants Outstanding	46,167
Remaining Contractual Life (in years)	3 months
Exercise Price Four [Member] \| Equity Option [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) \| $ / shares	$ 25
Number of warrants Outstanding	179,501
Remaining Contractual Life (in years)	4 years 1 month 9 days

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($)	1 Months Ended	12 Months Ended
Share-Based Compensation (Details) - USD ($)	May 28, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-Based Compensation (Details) [Line Items]
Authorized shares issuance to its employees, directors and consultants (in Shares)	4,150,704
Future grant share (in Shares)	1,451,043
Expire grant year	10 years
Weighted-average fair value at grant date of the options granted (in Dollars per share)		$ 6.23	$ 2.93	$ 5.29
The total intrinsic value of options granted and options exercised		$ 336,000
Share-based compensation expense			$ 1,347,000
Weighted average period			1 year 7 months 17 days
Employee Stock Option [Member]
Share-Based Compensation (Details) [Line Items]
Total unrecognized estimated compensation cost		$ 1,905
Weighted average period		1 year 6 months 29 days
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation (Details) [Line Items]
Share-based compensation expense		$ 1,024,000	$ 0

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of fair value of stock option weighted-average assumptions - Stock Option Plan [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-Based Compensation (Details) - Schedule of fair value of stock option weighted-average assumptions [Line Items]
Weighted Average Risk-free interest rate	0.82%	0.46%	1.67%
Dividend yield
Weighted Average Volatility factor	91.57%	76.32%	73.71%
Weighted Average Expected life of the options	5 years	6 years	5 years

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of options granted under the existing stock-option plans - Stock Option Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, Outstanding at beginning of the year	1,884,420	1,625,042	1,801,418
Weighted average exercise price, Outstanding at beginning of the year (in Dollars per share)	$ 5.52	$ 5.72	$ 4.33
Number of options, Granted	345,500	360,500	158,021
Weighted average exercise price, Granted (in Dollars per share)	$ 12.14	$ 4.46	$ 8.72
Number of options, Forfeited and expired	(48,242)	(63,376)	(128,256)
Weighted average exercise price, Forfeited and expired (in Dollars per share)	$ 33.11	$ 6.26	$ 5.24
Number of options, Exercised	(39,131)	(37,746)	(221,641)
Weighted average exercise price, Exercised (in Dollars per share)	$ 2.89	$ 2.69	$ 2.7
Number of options, Pre-merger Bioblast options			15,500
Weighted average exercise price, Pre-merger Bioblast options (in Dollars per share)			$ 90.17
Number of options, Outstanding at end of the year	2,142,547	1,884,420	1,625,042
Weighted average exercise price, Outstanding at end of the year (in Dollars per share)	$ 6.02	$ 5.52	$ 5.72
Number of options, Exercisable at end of the year	1,613,465	1,283,193	1,098,691
Weighted average exercise price, Exercisable at end of the year (in Dollars per share)	$ 4.9	$ 5.15	$ 3.71

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of changes in nonvested shares granted - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of changes in nonvested shares granted [Abstract]
Number of options, Balance at beginning of the year	601,227	526,351	774,836
Weighted average exercise price, Balance at beginning of the year	$ 5.93	$ 7.03	$ 5.7
Number of options, Granted	345,500	360,500	158,021
Weighted average exercise price, Granted	$ 12.14	$ 3.86	$ 8.72
Number of options, Vested during the year	(385,798)	(249,965)	(278,250)
Weighted average exercise price, Vested during the year	$ 7.39	$ 6.07	$ 5.21
Number of options, Forfeited during the year	(31,847)	(35,659)	(128,256)
Weighted average exercise price, Forfeited during the year	$ 6.75	$ 6.24	$ 5.24
Number of options, Balance at end of the year	529,082	601,227	526,351
Weighted average exercise price, Balance at end of the year	$ 8.69	$ 5.93	$ 7.03

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Schedule of exercise prices and remaining contractual life $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding	2,142,547
Intrinsic Value of Options Outstanding (in Dollars) \| $	$ 3,066,494
No. of options exercisable	1,613,465
Exercise Price One [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 2.69
Number of options outstanding	649,883
Average Remaining contractual Life (in years)	3 years 5 months 1 day
Intrinsic Value of Options Outstanding (in Dollars) \| $	$ 2,313,584
No. of options exercisable	649,883
Exercise Price Two [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 3.66
Number of options outstanding	250,000
Average Remaining contractual Life (in years)	8 years 4 months 2 days
Intrinsic Value of Options Outstanding (in Dollars) \| $	$ 646,750
No. of options exercisable	138,890
Exercise Price Three [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 4.68
Number of options outstanding	55,500
Average Remaining contractual Life (in years)	8 years 3 months
Intrinsic Value of Options Outstanding (in Dollars) \| $	$ 87,135
No. of options exercisable	13,875
Exercise Price Four [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 6.22
Number of options outstanding	634,177
Average Remaining contractual Life (in years)	5 years 6 months
Intrinsic Value of Options Outstanding (in Dollars) \| $	$ 19,025
No. of options exercisable	613,617
Exercise Price Five [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 8.19
Number of options outstanding	150,000
Average Remaining contractual Life (in years)	7 years 10 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	75,000
Exercise Price Six [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 8.23
Number of options outstanding	20,000
Average Remaining contractual Life (in years)	9 years 10 months 20 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable
Exercise Price Seven [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 8.3
Number of options outstanding	15,000
Average Remaining contractual Life (in years)	9 years 7 months 6 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable
Exercise Price Eight [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 9.02
Number of options outstanding	40,500
Average Remaining contractual Life (in years)	8 years 10 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	10,125
Exercise Price Nine [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 10.12
Number of options outstanding	12,126
Average Remaining contractual Life (in years)	6 years 11 months 4 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	9,700
Exercise Price Ten [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 12.21
Number of options outstanding	2,421
Average Remaining contractual Life (in years)	7 years 2 months 26 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	1,211
Exercise Price Eleven[Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 12.23
Number of options outstanding	250,000
Average Remaining contractual Life (in years)	9 years 4 months 28 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	69,444
Exercise Price Twelve [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 14
Number of options outstanding	60,500
Average Remaining contractual Life (in years)	9 years 3 months 25 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	30,250
Exercise Price Thirteen [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 21.4
Number of options outstanding	1,940
Average Remaining contractual Life (in years)	7 years 6 months 25 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	970
Exercise Price fourteen [Member] \| Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 90.16
Number of options outstanding	500
Average Remaining contractual Life (in years)	1 year 5 months 15 days
Intrinsic Value of Options Outstanding (in Dollars) \| $
No. of options exercisable	500

Share-Based Compensation (Det_6

Share-Based Compensation (Details) - schedule of information concerning restricted stock units granted - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation (Details) - schedule of information concerning restricted stock units granted [Line Items]
Number of shares Nonvested at beginning of period
Weighted average grant date fair value Nonvested at beginning of period
Number of shares Granted	236,706
Weighted average grant date fair value Granted	$ 10.22
Number of shares Vested
Weighted average grant date fair value Vested
Number of shares Forfeited	(7,375)
Weighted average grant date fair value Forfeited	$ 14.67
Number of shares Nonvested at end of period	229,331
Weighted average grant date fair value Nonvested at end of period	$ 10.08

Share-Based Compensation (Det_7

Share-Based Compensation (Details) - Schedule of share-based compensation expenses related to grants under the equity incentive plan - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation	$ 2,914	$ 670	$ 810
Research & development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation	1,210	401	607
General & administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation	$ 1,704	$ 269	$ 203

Taxes on Income (Details)

Taxes on Income (Details) $ in Millions	12 Months Ended
Taxes on Income (Details) $ in Millions	Dec. 31, 2021USD ($)
Taxes on Income (Details) [Line Items]
Israeli corporate tax rate	23.00%
Carry-forwards losses	$ 12.2
Parent [Member]
Taxes on Income (Details) [Line Items]
Carry-forwards losses	47
Enlivex R&D [Member]
Taxes on Income (Details) [Line Items]
Carry-forwards losses	$ 41

Taxes on Income (Details) - Sch

Taxes on Income (Details) - Schedule of provision for income taxes - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of provision for income taxes [Abstract]
Current tax
Deferred tax
Provision for income taxes, net

Taxes on Income (Details) - S_2

Taxes on Income (Details) - Schedule of reconciliation of the theoretical tax expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of reconciliation of the theoretical tax expenses [Abstract]
Loss before taxes	$ 14,468	$ 11,824	$ 9,384
Statutory tax rate	23.00%	23.00%	23.00%
Tax benefit	$ 3,328	$ 2,720	$ 2,158
Permanent differences	975	635	9,136
Valuation allowance	(4,303)	(3,355)	(11,294)
Tax expenses

Taxes on Income (Details) - S_3

Taxes on Income (Details) - Schedule of deferred tax liabilities and assets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of deferred tax liabilities and assets [Abstract]
Accrued employees’ and directors’ compensation	$ 308	$ 61
Stock based compensation	746
Research and development expenses	2,527	1,275
Net loss carryforward	22,444	18,760
Total deferred tax assets	26,025	20,096
Less - valuation allowance	(26,025)	(20,096)
Deferred tax assets

Balances and Transactions wit_3

Balances and Transactions with Related Parties (Details) - USD ($) $ in Thousands	May 12, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related Party Transactions [Abstract]
Related parties transaction, description	the agreed remuneration for work performed in accordance with the agreement until the date of termination; and (ii) in the event that the termination is not due to a breach of the agreement by the executive officer, the Company shall reimburse the executive officer for all documented expenses arising from non-cancellable commitments incurred prior to such termination. In consideration for the executive officer’s fulfilment of his obligations, the Company has agreed to pay a fixed price for each of the activities performed as defined in the agreement.
Research and development expenses		$ 1,331	$ 522	$ 251

Balances and Transactions wit_4

Balances and Transactions with Related Parties (Details) - Schedule of consolidated balance sheets - Balances and Transactions With Related Parties [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Condensed Balance Sheet Statements, Captions [Line Items]
Current Liabilities - Accounts payable trade	$ 275	$ 175
Current Liabilities - Accrued expenses	$ 115

Fair Value Measurement (Details

Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	$ 11,202	$ 5,673
Short term deposits	10,004	30,034
Cash held with respect to CVR Agreement	113	1,171
Marketable securities	62,924
Restricted cash	321	168
Total financial assets	84,564	37,046
Level 1 [Member]
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	11,202	5,673
Short term deposits	10,004	30,034
Cash held with respect to CVR Agreement	113	1,171
Marketable securities	62,924
Restricted cash	321	168
Total financial assets	84,564	37,046
Level 2 [Member]
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Cash held with respect to CVR Agreement
Marketable securities
Restricted cash
Total financial assets
Level 3 [Member]
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Cash held with respect to CVR Agreement
Marketable securities
Restricted cash
Total financial assets

Supplementary Financial State_3

Supplementary Financial Statement Information (Details) - Schedule of condensed income statement - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of condensed income statement [Abstract]
Payroll and related expenses	$ 5,054	$ 3,183	$ 2,259
Research and development services	4,557	2,438	2,682
Materials	1,505	612	454
Share Based Compensation	1,210	401	607
Depreciation	546	273	198
Other	1,029	394	486
Research and development expenses gross	13,901	7,301	6,686
Israel Innovation Authority participation in research and development costs and royalties payable	(1,020)	(1,215)	(1,082)
Research and development expenses net	12,881	6,086	5,604
Payroll expenses	1,138	737	569
Compensation to directors	1,168	862	526
Professional fees	1,080	995	845
Office maintenance and office expenses	167	97	145
Insurance	783	486	243
Share Based Compensation	1,704	269	203
Other	367	253	484
General and administrative expenses	6,407	3,699	3,015
Interest income	120	225	238
Income related to marketable securities	5,590
Exchange differences, net	(562)	(2,258)	(945)
Bank commissions and other expenses	(328)	(6)	(58)
Financial expenses	$ 4,820	$ (2,039)	$ (765)

Events Subsequent to the Bala_2

Events Subsequent to the Balance Sheet Date (Details) - Subsequent Event [Member] $ in Millions	1 Months Ended
	Jan. 31, 2022USD ($)
Events Subsequent to the Balance Sheet Date (Details) [Line Items]
Amount of grants expenditure	$ 4.8
Expects to receive an IIA grant and not expenses associated	$ 1